You are viewing a free limited preview of Zafgen, Inc.
Get Full Access To This Report 
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
Zafgen, Inc. is a privately-held, venture capital backed biopharmaceutical company that focuses on developing obesity therapeutics based on vascular targeting in adipose tissue (fat). Founded in 2005 by Maria Rupnick, Zafgen, Inc. is headquartered in Cambridge, Massachusetts.
| Company Tags: | VC Backed |
| Year Founded: | 2005 |
| Fiscal Year End: | 12/31 |
| City: | Cambridge |
| State/Province: | Massachusetts |
| Country: | United States |
| Phone: | View |
| Website: | www.zafgen.com |
| Brands: | ZGN-433 |
| Technology > Biotechnology > Biotherapeutics |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
$99 Single Company AccessInstant Full Site-Wide Access| Date | Investor | Round | Investor Type | |
| Aug. 2006 | View | A | Venture Capital | |
| Aug. 2006 | View | A | Venture Capital | |
| Details | Total Round A View | |||
| Mar. 2010 | View | B | Venture Capital | |
| Mar. 2010 | View | B | Venture Capital | |
| Mar. 2010 | View | B | Venture Capital | |
| Details | Total Round B1 View | |||
| Jul. 2011 | View | C | Venture Capital | |
| Jul. 2011 | View | C | Venture Capital | |
| Details | Total Round C View | |||
| Dec. 2012 | View | D | Venture Capital | |
| Dec. 2012 | View | D | Venture Capital | |
| Dec. 2012 | View | D | Venture Capital | |
| Details | Total Round D View | |||
| Total of Funding Shown Above View | ||||
| 1 | The round was made up...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide AccessZafgen, Inc. Phase 1 and Phase 2 Trials of ZGN-433
Zafgen, Inc.'s flagship experimental drug is a methionine aminopeptidase 2 (MetAP2) inhibitor called ZGN-433. In early 2011, Zafgen, Inc. established in Phase 1 clinical… Continue Reading →
$99 Single Company AccessInstant Full Site-Wide Access|
Get Full Access To This Report
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
PrivCo is the authority for financial & business data on major private companies, including:
| Private Companies | 209,150 |
| Private Investors | 12,004 |
| Private M&A Deals | 43,155 |
| VC/Funding Rounds | 36,088 |
| Total Data Points | 95,786,176 |
You are viewing a free limited preview of Zafgen, Inc.
PrivCo is the premier source for business and financial data on major, non-publicly traded corporations, including family owned, private equity owned, venture backed, and international unlisted companies. Click here to learn more.
PDF VERSION: Download Company Report in PDF Format
EXPORT COMPANY'S DATA TO EXCEL:
Full Online Report